Aprecia's 3D Printed Pills Are Closer to Mass Production

Aprecia Pharmaceuticals is 22 months into a 28-month DARPA project aimed at proving that 3D printed drugs can be manufactured onshore in the US and approved by the FDA. The project, called EQUIP-A-Pharma, pairs Aprecia with Battelle to build a compact, mobile manufacturing line that produces active pharmaceutical ingredients and final dosage forms using Aprecia's proprietary ZipDose binder jetting process.

The goal is to file two drugs for Abbreviated New Drug Application approval by the time the contract ends. If the FDA accepts the submissions, it would extend Aprecia's lead in 3D printed pharmaceuticals. The company already holds the only FDA approval for a 3D printed prescription drug, Spritam, which it launched in 2015 after licensing IP from MIT.

Aprecia's manufacturing approach differs from conventional batch production. Its system captures data continuously during printing, tracking parameters like powder flow, liquid deposition, drying conditions, tablet weight, and spectroscopy readings. The company says this creates a blockchain-like record for each tablet, making it possible to release batches faster because quality is proven in real time rather than inferred from spot checks.

The DARPA program also tests whether a small-footprint, mobile production unit can reliably manufacture drugs during a shortage. The US government wants a method that can be moved and deployed quickly, and Aprecia's system fits that brief. Battelle contributes its small-scale chemical synthesis platform to the partnership, handling the active ingredient side while Aprecia handles the final 3D printed tablet.

There is still work to do before 3D printed drugs become routine. Aprecia must scale from a demonstration unit to full commercial output, and the FDA must actually approve the ANDA filings. The company is also expanding beyond oral solid dosage forms, though it has not announced specific new products. For now, the near-term win is proving that a DARPA-funded pilot can meet real-world regulatory standards.